G. Al-Atrash

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.

M. Konopleva, X. Bao, J. Taub, 2023, Biochemical pharmacology.

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis

M. Konopleva, S. Wiley, X. Bao, 2023, Research square.

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

S. Colla, R. Kanagal-Shamanna, Hui Yang, 2024, Cell reports. Medicine.

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia

S. Colla, G. Garcia-Manero, Koichi Takahashi, 2023, bioRxiv.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Linghua Wang, Koichi Takahashi, J. Westin, 2023, Cell reports. Medicine.